Search

Your search keyword '"Morrone, Helen Linda"' showing total 3 results
Start Over Author "Morrone, Helen Linda" Topic monoclonal antibodies
3 results on '"Morrone, Helen Linda"'

2. Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study

Author

Scaglione, Vincenzo, Rotundo, Salvatore, Marascio, Nadia, De Marco, Carmela, Lionello, Rosaria, Veneziano, Claudia, Berardelli, Lavinia, Quirino, Angela, Olivadese, Vincenzo, Serapide, Francesca, Tassone, Bruno, Morrone, Helen Linda, Davoli, Chiara, La Gamba, Valentina, Bruni, Andrea, Cesana, Bruno Mario, Matera, Giovanni, Russo, Alessandro, Costanzo, Francesco Saverio, Viglietto, Giuseppe, Trecarichi, Enrico Maria, and Torti, Carlo

Published
2022
Full Text
View/download PDF

3. Interleukin-62/lymphocyte as a proposed predictive index for COVID-19 patients treated with monoclonal antibodies.

Author

Rotundo, Salvatore, Borelli, Massimo, Scaglione, Vincenzo, Lionello, Rosaria, Biamonte, Flavia, Olivadese, Vincenzo, Quirino, Angela, Morrone, Helen Linda, Matera, Giovanni, Costanzo, Francesco Saverio, Russo, Alessandro, Trecarichi, Enrico Maria, Torti, Carlo, IDTM UMG COVID-19 Group, Serapide, Francesca, Tassone, Bruno, Fusco, Paolo, Davoli, Chiara, La Gamba, Valentina, and Berardelli, Lavinia

Subjects
COVID-19, MONOCLONAL antibodies, CONVENIENCE sampling (Statistics), ASYMPTOMATIC patients, DISEASE progression
Abstract

In a convenience sample of 93 patients treated with monoclonal antibodies (moAbs) against SARS-CoV-2, the interleukin-62/lymphocyte count ratio (IL-62/LC) was able to predict clinical worsening both in early stages of COVID-19 and in oxygen-requiring patients. Moreover, we analysed 18 most at-risk patients with asymptomatic or mild disease treated with both moAbs and antiviral treatment and found that only 2 had clinical progression, while patients with a similar risk were reported to have an unfavourable outcome in most cases from recent data. In only one of our 18 patients, clinical progression was attributable to COVID-19, and in the other cases, clinical progression was observed despite IL-62/LC being above the risk cut-off. In conclusion, IL-62/LC may be a valuable method to identify patients requiring more aggressive treatments both in earlier and later stages of the disease; however, most at-risk patients can be protected from clinical worsening by combining moAbs and antivirals, even if levels of the IL-62/LC biomarker are lower than the risk cut-off. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results